For example, associations were found between a common variation at the leucine-rich repeat kinase 2 (LRRK2) locus and survival from symptom onset to death in patients with PSP, which might be mediated by the effect of increased LRRK2 expression in microglia pro-inflammatory responses.15 Plasma NfL has been highlighted as a promising marker for disease progression and as a useful trial end point in patients with FTLD.57-59 Adding NfL levels to the survival model resulted in the cytokine-derived component retaining its predictive value. The gene discussed is LRRK2; the disease is supranuclear palsy, progressive, 1.